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1. INTRODUCTION {#jgf2214-sec-0005}
===============

Hypertension and obstructive sleep apnea (OSA) are both common conditions in the general population. Recent studies have estimated 30%‐50% of patients with hypertension have OSA which might be underestimated, though the prevalence in the PC setting is unclear.[1](#jgf2214-bib-0001){ref-type="ref"}, [2](#jgf2214-bib-0002){ref-type="ref"}, [3](#jgf2214-bib-0003){ref-type="ref"}, [4](#jgf2214-bib-0004){ref-type="ref"}

Understanding the prevalence and characteristics of OSA in PC patients with hypertension enables us to develop efficient diagnostic strategies. These strategies could improve the quality of hypertension and sleep disorder management in PC setting. Thus, our study aimed to explore the prevalence and characteristics of OSA in patients with hypertension and develop a diagnostic algorithm for unrecognized moderate or severe OSA in patients with hypertension in the PC setting.

2. MATERIALS AND METHODS {#jgf2214-sec-0006}
========================

In this multicenter cross‐sectional study, a convenience sample of eligible patients (aged 18 years or older and diagnosed with hypertension) was enrolled during visits to one of five clinics in Japan from October 2012 to September 2014. We excluded patients who met any of the following criteria: already diagnosed with OSA, moderate or severe heart failure, chronic obstructive pulmonary disease, or dementia.

This study was approved by the ethics committee of Mito Kyodo General Hospital and was conducted according to the principles expressed in the Declaration of Helsinki. Study participants provided written informed consent.

2.1. Data collection {#jgf2214-sec-0007}
--------------------

We used medical records to collect data on patients' characteristics, which included age, gender, body mass index (BMI), office blood pressure, comorbidities (diabetes mellitus, atrial fibrillation, ischemic heart disease, and cerebrovascular disease), number of antihypertensive drugs, current smoking status, regular alcohol use, and regular use of benzodiazepines. Physicians asked the patients who agreed to participate in the study if they have following six signs and symptoms: excessive daytime sleepiness; non‐restorative sleep; fatigue; insomnia; waking up with breath holding, gasping, or choking; and habitual snoring, breathing interruptions, or both noted by a bed partner or other observer. Subsequently, we assessed AHI and oxygen desaturation index (ODI) to obtain the frequency of respiratory events by using home sleep apnea testing (HSAT). We defined AHI as the average number of apneas and hypopneas per hour of sleep and ODI as the number of events per hour of recorded time in which blood oxygen saturation fell by ≥3%.

2.2. Statistical analysis {#jgf2214-sec-0008}
-------------------------

We diagnosed OSA according to ICSD‐2 criteria proposed by American Academy of Sleep Medicine.[5](#jgf2214-bib-0005){ref-type="ref"} We classified AHI ≥ 22 on HSAT as moderate or severe OSA and 22 \> AHI ≥ 5 as mild OSA based on a previous study.[6](#jgf2214-bib-0006){ref-type="ref"} Differences in characteristics between patients who underwent home sleep apnea testing (HSAT) and those who did not were compared using Student\'s *t* test for continuous variables and Pearson\'s chi‐square test or Fisher\'s exact test for categorical variables. Subsequently, we developed a diagnostic algorithm using nine variables: age (≥50 years or \<50 years), gender, BMI ≥ 27, office systolic blood pressure ≥140, office diastolic blood pressure ≥90, use of ≥3 antihypertensive drugs, current smoker, regular alcohol use, and regular use of benzodiazepines, for moderate or severe OSA using classification and regression tree analysis. *P*‐values were based on two‐sided tests and considered statistically significant at \<0.05. General statistical analyses were performed with SPSS version 24.0‐J (SPSS‐Japan, Tokyo, Japan).

3. RESULTS {#jgf2214-sec-0009}
==========

A total of 119 patients met the inclusion criteria, but 42 did not subsequently undergo HSAT and one had missing HSAT data. We developed the diagnostic algorithm based on data from 76 patients who underwent HSAT. Patient characteristics are summarized in Table [1](#jgf2214-tbl-0001){ref-type="table"}. Forty‐nine patients (64.5%) had AHI ≥ 22, and 24 patients (31.6%) had 22 \> AHI ≥ 5. Fifteen of 32 female patients (46.9%) and 13 of 28 postmenopausal female patients (46.4%) had AHI ≥ 22.

###### 

Characteristics of study patients

                                            All patients (n = 119)   \%     Patients who underwent home sleep apnea testing (n = 77)   \%     Patients who did not undergo home sleep apnea testing (n = 42)   \%     *P*
  ----------------------------------------- ------------------------ ------ ---------------------------------------------------------- ------ ---------------------------------------------------------------- ------ -------
  Gender                                                                                                                                                                                                              
   Male                                     73                       61.3   45                                                         58.4   28                                                               66.7   0.434
   Female                                   46                       38.7   32                                                         41.6   14                                                               33.3   
  Mean age ± standard deviation (years)     65.1 ± 11.7                     63.6 ± 11.7                                                       68.0 ± 11.1                                                             0.045
   Age \<50 years                           17                       14.3   13                                                         16.9   4                                                                9.5    0.412
  Body mass index (kg/m^2^)                                                                                                                                                                                           
   Mean ± standard deviation                25.4 ± 3.5                      25.3 ± 3.7                                                        25.4 ± 3.1                                                              0.868
   Range                                    19.1‐38.8                       19.8‐38.8                                                         19.1‐33.7                                                               
   ≥27 kg/m^2^                              37                       31.1   25                                                         32.5   12                                                               28.6   0.685
  Office systolic blood pressure (mm Hg)                                                                                                                                                                              
   Mean ± standard deviation                140.7 ± 14.3                    141.7 ± 13.3                                                      138.8 ± 15.9                                                            0.302
   ≥140 mm Hg                               67                       56.3   47                                                         61.0   20                                                               47.6   0.179
  Office diastolic blood pressure (mm Hg)                                                                                                                                                                             
   Mean ± standard deviation                82.9 ± 11.4                     83.3 ± 10.7                                                       82.0 ± 12.8                                                             0.559
   ≥90 mm Hg                                34                       28.6   20                                                         26.0   14                                                               33.3   0.525
  Antihypertensive drug                     1.9 ± 0.8                       1.9 ± 0.8                                                         2.0 ± 0.9                                                               0.557
   ≥3 antihypertensive drugs                24                       20.2   15                                                         19.5   9                                                                21.4   0.814
  Current smoker                            17                       14.3   12                                                         15.6   5                                                                11.9   0.785
  Regular alcohol use                       62                       52.1   44                                                         57.1   18                                                               42.9   0.128
  Comorbidities                                                                                                                                                                                                       
   Ischemic heart disease                   4                        3.4    3                                                          3.9    1                                                                2.4    1.00
   Cerebrovascular disease                  8                        6.7    7                                                          9.1    1                                                                2.4    0.257
   Atrial fibrillation                      4                        3.4    3                                                          3.9    1                                                                2.4    1.00
   Diabetes mellitus                        31                       26.1   16                                                         20.8   15                                                               35.7   0.085
  Regular use of benzodiazepines            22                       18.5   12                                                         15.6   10                                                               23.8   0.325
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The classification and regression tree analysis generated two classification splits for the high‐risk groups (75% to \<90% prevalence) and intermediate‐risk groups (\<75% prevalence) for moderate or severe OSA (Figure [1](#jgf2214-fig-0001){ref-type="fig"}). The high‐risk group included male patients, and female patients taking ≥3 antihypertensive drugs. Female patients not taking ≥3 antihypertensive drugs were placed in the intermediate‐risk group.

![The high‐risk group had a 75% to \<90% prevalence of moderate or severe OSA, and the intermediate‐risk group had a \< 75% prevalence of moderate or severe OSA](JGF2-20-39-g001){#jgf2214-fig-0001}

4. DISCUSSION {#jgf2214-sec-0010}
=============

This is the first multicenter cross‐sectional study to explore the prevalence and characteristics of OSA and develop a diagnostic algorithm for unrecognized moderate or severe OSA among PC patients with hypertension.

The most important finding of this study was that 64.5% of patients had AHI ≥ 22, which fulfills the diagnostic criteria for moderate or severe OSA in patients with hypertension.[7](#jgf2214-bib-0007){ref-type="ref"} This prevalence is much higher than in a recent study that estimated the prevalence of with hypertension to be 30%‐50%[1](#jgf2214-bib-0001){ref-type="ref"}, [4](#jgf2214-bib-0004){ref-type="ref"}. One possible reason for the high prevalence of OSA in PC patients with hypertension is that we might have missed patients with hypertension who do not have obvious signs and symptoms of OSA in the PC setting until now. Thus, our results imply that many patients with hypertension in the PC setting need to be assessed for obstructive respiratory events during sleep.

The second important finding of this study was that we developed a diagnostic algorithm for unrecognized moderate or severe OSA. The diagnostic algorithm indicates that we should pay attention to detecting moderate or severe OSA in specific patients: male patients with hypertension, or female patients taking ≥3 antihypertensive drugs. This algorithm enables us to easily recognize the patients with hypertension who have a high risk of moderate or severe OSA, and accurately recommend HSAT for patients with hypertension in the PC setting.

Of note that our study revealed that female hypertension patients have high pretest possibility of moderate or severe OSA. This result implies that we should assess the obstructive respiratory events for female patients with hypertension as well as male patients.

The major limitations of this study were that we enrolled patients using convenience sampling, and the number of patients who did not undergo HSAT is large in comparison with those eligible in this study, though there was no significant difference except for mean age. And that this study had a small sample size despite being a multicenter study. Therefore, the validation is needed for clinical applications and caution is needed when interpreting the results.

5. CONCLUSION {#jgf2214-sec-0011}
=============

The prevalence of OSA among PC patients with hypertension might be much higher than previously thought. In the PC setting, patients with hypertension who have specific risk factors for OSA should undergo assessment for obstructive respiratory events during sleep.
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